1	2	3
13	M/s. Fulford (I) Ltd. (Gantamycin)	194.62
14	M/s. Nicholas Labs. (Gentamycin)	53.03
15	M/s. Burroughs Wellcome (Sulphamathoxazole)	441.27
16	M/s. Lyka Labs. (Fluocinolone Acetonide)	678.73
17	M/s. Glaxo India Ltd. (Betamethasone & Salts)	7178.18

Basis of drug prices equalisation account's claims

1622. SHRI H. HANUMANTHAPPA: CHOWDHARY RAM SEWAK:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M/s. Glaxo created a provision of Rs. 30.87 crores in their balance sheet for the year 1988-89 for DPEA claims based on the Judgement of High Court;

(b) whether it is also a fact that this money was used by the company without any interest and no income tax was paid; and

(c) what is the break up of this amount yearwise?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) The information as supplied by the Company itself regarding provision made in its books for DPEA claims is given in the statement attached. The matter relating to recoveries from M/s. Glaxo is the subject matter of a Writ Petition in the Delhi High Court and is, therefor sub-Judice.

Statement

Yearwise Details of provisions in the Books for DPEA Claims

Rs. in Lakhs

	Provision for the year	Cumulative
1981-82	485.77	485.77
1982-83	481.13	966.90
1983-84	526.76	1493.66
1984-85	612.33	2105.99
1985-86	680.64	2786.63
1986-87 (Net of writeback arising out of Order of 20-11-86)	770.57	2957.20
1987-88	128.64	3085.84
1988-89 (Writeback arising out of order of 2-1-89)	522.74	2563·10